Although corticosteroids and drugs such as azathioprine still have a role, there is increasing use of newer potent immunosuppressants. Many of these drugs act on T-lymphocytes. Tacrolimus is a calcineurin inhibitor which has a similar mechanism of action to cyclosporin, reducing T-cell differentiation. Sirolimus and everolimus bind to the same protein as tacrolimus, but have a different mechanism of action. As some of these drugs have a narrow therapeutic range, drug concentrations must be monitored. Mycophenolate is an inhibitor of purine synthesis. Another approach is to block the receptors on T-cells with immunosuppressant antibodies such as basiliximab, daclizumab and muromonab-CD3.
Introduction
Immunosuppressants are essential for successful organ transplantation and the treatment of many autoimmune disorders. They suppress rejection and dampen the autoimmune process, but they also lead to the undesired consequences of immunodeficiency, such as infection or malignancy, and non-immune toxicity. 1 Glucocorticoids and thiopurines such as azathioprine are still widely used, but newer potent drugs have become the cornerstone of many treatments.
Azathioprine
Azathioprine is a prodrug which is converted to Improved understanding of its pharmacogenetics has led to the safer use of azathioprine. A major influence on thiopurine therapy is the inherited activity of thiopurine methyltransferase.
This enzyme shunts thiopurine to relatively inactive compounds. A deficiency of thiopurine methyltransferase is associated with grossly elevated concentrations of thioguanine nucleotides and severe haematological toxicity (agranulocytosis). Where laboratory assays are available, measuring thiopurine methyltransferase activity before starting azathioprine therapy may be advisable to identify patients at risk of acute haematological toxicity. 2 The other major purine metabolic pathway involves xanthine oxidase. In patients taking azathioprine, use of a xanthine oxidase inhibitor such as allopurinol may result in severe myelotoxicity.
Calcineurin inhibitors
Calcineurin catalyses some of the intracellular processes associated with the activation of T-lymphocytes. When calcineurin inhibitors bind to intracellular proteins called immunophilins, they block the effect of calcineurin. This results in reduced production of interleukin-2 and reduced proliferation of T-cells.
The nephrotoxicity of calcineurin inhibitors has emerged as an increasing cause of late renal allograft loss. The pathogenesis appears to be multifactorial and includes calcineurin-induced vasoconstriction, calcineurin-induced release of endothelin-1 (a potent vasoconstrictor), decreased production of the vasodilator nitric oxide, and increased expression of transforming growth factor beta 1 (a key cytokine associated with interstitial fibrosis). 3 Reducing the dose of calcineurin inhibitor, or using protocols including mycophenolate and sirolimus, may minimise the risk of nephrotoxicity and improve allograft and patient survival.
Cyclosporin
Since the early 1980s, cyclosporin has been the primary Adverse effects in common with cyclosporin include hypertension, nephrotoxicity and the haemolytic uraemic syndrome. Tacrolimus is less likely to cause hyperlipidaemia, hirsutism and gingival hypertrophy, but diabetes is more commonly associated. Trough whole blood concentrations should be monitored along with renal and hepatic function. As with cyclosporin, tacrolimus is also a substrate of CYP3A4 and subject to the same interactions.
Antiproliferative drugs
Sirolimus (rapamycin) and everolimus are structurally very similar and have the same mechanism of action. Like tacrolimus, they bind to FK-binding protein, but they have no effect on calcineurin. Instead, the complex inhibits a protein kinase that is critical for cell cycle progression. This kinase is known as the mammalian target of rapamycin (mTOR).
Inhibition of mTOR suppresses cytokine driven T-lymphocyte proliferation and activation, resulting in immunosuppression.
The main difference between sirolimus and everolimus is that the half-life of sirolimus (60 hours 
Mycophenolate
Mycophenolate is the prodrug of mycophenolic acid which inhibits purine synthesis by inhibiting inosine monophosphate dehydrogenase. Currently two products are available in Australia -mycophenolate mofetil and mycophenolate sodium. 
Immunosuppressant antibodies

Antithymocyte globulin
This is a polyclonal IgG antibody from horses or rabbits immunised with human thymocytes. Infusions of antithymocyte globulin cause profound T-cell depletion and the lymphopenia typically persists beyond one year. An unwanted effect is the release of cytokines. This is associated with the 'cytokine release syndrome' characterised by fever, rigors and hypotension.
Antibodies against CD25
Basiliximab and daclizumab are monoclonal antibodies against CD25, a receptor on the surface of T-lymphocytes. They are indicated for prophylaxis of acute rejection in renal transplantation.
The antibodies bind to and block the interleukin-2 receptor α-chain 
Muromonab-CD3
This is a mouse-derived monoclonal antibody which binds to the CD3 component of the T-cell receptor complex leading to T-cell depletion. Muromonab is also associated with the cytokine release syndrome which can range from a mild self-limiting flu-like illness to more serious manifestations including pulmonary oedema and neuropsychiatric adverse reactions.
Neutralising antibodies can develop which block the effect and limit the re-use of muromonab-CD3. A longer-term concern is the increased incidence of lymphoma.
Conclusion
Advances in transplantation and the treatment of immune disorders have paralleled the development of immunosuppressant drugs. While the newer drugs are associated with superior efficacy, this may come at the cost of a greater incidence of opportunistic infections and malignancy, and adverse effects such as chronic allograft nephropathy, hyperglycaemia and hyperlipidaemia. Accurate concentration monitoring of cyclosporin, tacrolimus, sirolimus, everolimus and probably mycophenolate is necessary to improve outcomes and minimise toxicity.
